The Regulation of the P53-mediated Stress Response by MDM2 and MDM4

Overview

Journal Cold Spring Harb Perspect Biol

Specialties Biology
Molecular Biology

Date 2010 Feb 26

PMID 20182601

Citations 47

Authors

Mary Ellen Perry

Affiliations

Soon will be listed here.

Abstract

Exquisite control of the activity of p53 is necessary for mammalian survival. Too much p53 is lethal, whereas too little permits tumorigenesis. MDM2 and MDM4 are structurally related proteins critical for the control of p53 activity during development, homeostasis, and the response to stress. These two essential proteins regulate both the activation of p53 in response to stress and the recovery of cells following resolution of the damage, yet both are oncogenic when overexpressed. Thus, multiple regulatory circuits ensure that their activities are fine-tuned to promote tumor-free survival. Numerous diverse stressors activate p53, and much research has gone into trying to find commonalities between them that would explain the mechanism by which p53 becomes active. It is now clear that although these diverse stressors activate p53 by different biochemical pathways, one common feature is the effort they direct, through a variety of means, toward disrupting the functions of both MDM2 and MDM4. This article provides an overview of the relationship between MDM2 and MDM4, features the various biochemical mechanisms by which p53 is activated through inhibition of their functions, and proposes some emerging areas for investigation of the p53-mediated stress response.

Citing Articles

Human cell-expressed tag-free rhMFG-E8 as an effective radiation mitigator.

Chaung W, Ma G, Jacob A, Brenner M, Wang P Sci Rep. 2023; 13(1):22186.

PMID: 38092894 PMC: 10719321. DOI: 10.1038/s41598-023-49499-y.

Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths.

Cortes-Lopez M, Chamely P, Hawkins A, Stanley R, Swett A, Ganesan S Cell Stem Cell. 2023; 30(9):1262-1281.e8.

PMID: 37582363 PMC: 10528176. DOI: 10.1016/j.stem.2023.07.012.

MDM2-BCL-X PROTACs enable degradation of BCL-X and stabilization of p53.

Chang M, Gao F, Chen J, Gnawali G, Wang W Acta Mater Med. 2023; 1(3):333-342.

PMID: 36910255 PMC: 10004178. DOI: 10.15212/amm-2022-0022.

Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways.

Lin H, Sun F, Li T, Zhang Y, Guo X, Li M Cancer Chemother Pharmacol. 2022; 90(6):455-465.

PMID: 36251033 DOI: 10.1007/s00280-022-04481-9.

Discrete Logic Modeling of Cell Signaling Pathways.

Ikonomi N, Werle S, Schwab J, Kestler H Methods Mol Biol. 2022; 2488:159-181.

PMID: 35347689 DOI: 10.1007/978-1-0716-2277-3_12.

References

Christophorou M, Ringshausen I, Finch A, Swigart L, Evan G . The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature. 2006; 443(7108):214-7. DOI: 10.1038/nature05077. View

Mendrysa S, Perry M . The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress. Mol Cell Biol. 2000; 20(6):2023-30. PMC: 110819. DOI: 10.1128/MCB.20.6.2023-2030.2000. View

Chavez-Reyes A, Parant J, Amelse L, Montes de Oca Luna R, Korsmeyer S, Lozano G . Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res. 2003; 63(24):8664-9. View

Sharp D, Kratowicz S, Sank M, GEORGE D . Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem. 1999; 274(53):38189-96. DOI: 10.1074/jbc.274.53.38189. View

Westphal C, Hoyes K, Canman C, Huang X, Kastan M, Hendry J . Loss of atm radiosensitizes multiple p53 null tissues. Cancer Res. 1998; 58(24):5637-9. View

Pereg Y, Lam S, Teunisse A, Biton S, Meulmeester E, Mittelman L . Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol Cell Biol. 2006; 26(18):6819-31. PMC: 1592859. DOI: 10.1128/MCB.00562-06. View

Stracker T, Usui T, Petrini J . Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst). 2009; 8(9):1047-54. PMC: 2725228. DOI: 10.1016/j.dnarep.2009.04.012. View

Pan Y, Chen J . MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol. 2003; 23(15):5113-21. PMC: 165735. DOI: 10.1128/MCB.23.15.5113-5121.2003. View

Batchelor E, Loewer A, Lahav G . The ups and downs of p53: understanding protein dynamics in single cells. Nat Rev Cancer. 2009; 9(5):371-7. PMC: 2892289. DOI: 10.1038/nrc2604. View

10.

Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G . Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A. 2006; 103(9):3232-7. PMC: 1413884. DOI: 10.1073/pnas.0508476103. View

11.

Barboza J, Iwakuma T, Terzian T, El-Naggar A, Lozano G . Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res. 2008; 6(6):947-54. PMC: 2699947. DOI: 10.1158/1541-7786.MCR-07-2079. View

12.

Brash D, Rudolph J, Simon J, Lin A, McKenna G, Baden H . A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991; 88(22):10124-8. PMC: 52880. DOI: 10.1073/pnas.88.22.10124. View

13.

Grier J, Xiong S, Elizondo-Fraire A, Parant J, Lozano G . Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol. 2005; 26(1):192-8. PMC: 1317622. DOI: 10.1128/MCB.26.1.192-198.2006. View

14.

Atwal G, Kirchhoff T, Bond E, Montagna M, Monagna M, Menin C . Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci U S A. 2009; 106(25):10236-41. PMC: 2700939. DOI: 10.1073/pnas.0901298106. View

15.

Efeyan A, Murga M, Martinez-Pastor B, Ortega-Molina A, Soria R, Collado M . Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS One. 2009; 4(5):e5475. PMC: 2675057. DOI: 10.1371/journal.pone.0005475. View

16.

Wang Y, Leblanc M, Wade M, Jochemsen A, Wahl G . Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell. 2009; 16(1):33-43. PMC: 2758524. DOI: 10.1016/j.ccr.2009.05.008. View

17.

Bond G, Hu W, Bond E, Robins H, Lutzker S, Arva N . A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5):591-602. DOI: 10.1016/j.cell.2004.11.022. View

18.

Chen L, Gilkes D, Pan Y, Lane W, Chen J . ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 2005; 24(19):3411-22. PMC: 1276172. DOI: 10.1038/sj.emboj.7600812. View

19.

Montes de Oca Luna R, Wagner D, Lozano G . Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995; 378(6553):203-6. DOI: 10.1038/378203a0. View

20.

Migliorini D, Denchi E, Danovi D, Jochemsen A, Capillo M, Gobbi A . Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol. 2002; 22(15):5527-38. PMC: 133932. DOI: 10.1128/MCB.22.15.5527-5538.2002. View